CDXS vs RVTY Stock Comparison

Codexis and Revvity Prices as of Oct 26, 2026 Peers: Industry group
CDXS Codexis, Inc.
$1.30 -1.5% 1M -51.9% 1Y
Market cap
$115.64M
P/E
–
Revenue (TTM)
$77.68M
Div. yield
–
Life Sciences Tools Healthcare
2 wins
RVTY Revvity, Inc.
$160.32 +6.1% 1M +62.1% 1Y
Market cap
$18.07B
P/E
76.0x
Revenue (TTM)
$2.91B
Div. yield
0.00%
Life Sciences Tools Healthcare
7 wins

Head to Head

9 decided of 12

Revvity leads on 7 of the 12 questions below (Revvity 7, Codexis 2). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionCDXSRVTYLeader
Larger companyMarket capitalisation $115.64M $18.07B RVTY
Cheaper on earningsLower P/E, profitable companies only -3.8x 76.0x –
Cheaper on forward earningsLower price / next fiscal year consensus EPS — 31.4x –
Faster revenue growthRevenue growth, trailing twelve months +35.9% +4.1% CDXS
More profitableNet margin, trailing twelve months -39.6% 8.2% RVTY
Better return on capitalReturn on invested capital -35.1% 3.1% RVTY
Less leveragedLower net debt / EBITDA 0.7x 2.8x CDXS
Higher dividend yieldTrailing dividend yield 0.00% 0.00% –
Better 1-year returnPrice return, last 12 months -51.9% +62.1% RVTY
Better 5-year returnAnnualised price return, 5 years -47.8%/yr -1.6%/yr RVTY
Less volatileAnnualised volatility, 1 year 86.8% 39.9% RVTY
Higher overall scoreMean of the five percentile scores vs peers 44/100 58/100 RVTY

Percentile Scorecard

CDXSRVTY

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisCDXSRVTY
Valuation 40 #138 of 228 68 #73 of 228
Growth 67 #74 of 221 27 #161 of 221
Profitability 43 #119 of 208 79 #45 of 208
Financial Health 30 #167 of 239 47 #128 of 239
Shareholder Returns 43 #79 of 137 69 #43 of 137
Overall 44 58
  • CDXS ranked among 248 companies in Medical Devices and Diagnostics
  • RVTY ranked among 248 companies in Medical Devices and Diagnostics

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodCDXSRVTYSPY
1 month -1.5%+6.1% -0.8%
3 months -16.1%+48.4% +3.5%
6 months -50.9%+84.7% +7.0%
Year to date -20.2%+65.7% +12.2%
1 year -51.9%+62.1% +13.0%
3 years -16.1%+63.8% +86.3%
3 years, per year -5.7%+17.9% +23.1%
5 years -96.1%-7.8% +68.6%
5 years, per year -47.8%-1.6% +11.0%
10 years -70.5%+216.8% +258.0%
10 years, per year -11.5%+12.2% +13.6%

Risk

MeasureCDXSRVTYSPY
Volatility, 1Y 86.8%39.9% 12.7%
Downside volatility, 1Y 91.4%35.7% 12.7%
Beta vs S&P 500, 1Y 1.861.22 1.00
Return / volatility, 1Y -0.601.56 1.02
Max drawdown, 5Y -97.7%-59.2% -25.4%
From 52-week high -54.4%0.0% -1.8%
52-week high $2.85$160.32 $779.14
52-week low $0.98$82.26 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleCDXSRVTY
P/E now vs peer median -3.9xmedian 30.6x 75.3xmedian 30.6x
P/S now vs peer median 1.5xmedian 3.0x 6.1xmedian 3.0x
EV/EBITDA now vs peer median -5.0xmedian 17.5x 25.9xmedian 17.5x
P/FCF now vs peer median -9.8xmedian 23.3x 31.4xmedian 23.3x
P/B now vs peer median 3.6xmedian 2.4x 2.5xmedian 2.4x
PEG now vs peer median -0.15median 0.87 -2.42median 0.87

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsCDXSRVTY
Revenue $77.68M $2.91B
Gross profit $67.60M $1.60B
Operating income -$27.66M $358.85M
Net income -$30.72M $237.55M
Free cash flow -$12.18M $568.85M
R&D $48.74M $215.83M
EPS (diluted) $-0.34 $2.13
Cash & equivalents $27.17M $1.02B
Total debt $40.88M $3.21B
Shares (diluted) 91.05M 111.63M
Enterprise value -$141.41M $14.33B

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricCDXSRVTY
P/E -3.9x 75.3x
P/FCF -9.8x 31.4x
P/Operating cash flow -11.4x 28.0x
P/S 1.5x 6.1x
P/B 3.6x 2.5x
P/Tangible book 3.6x 3.6x
EV/EBITDA -5.0x 25.9x
EV/EBIT -3.8x 55.9x
EV/Revenue 1.3x 6.9x
EV/FCF -8.6x 35.3x
EV/Operating cash flow -10.1x 31.4x
PEG (3Y EPS CAGR) -0.15 -2.42

Growth

14 metrics
MetricCDXSRVTY
Revenue growth (1Y) 35.9% 4.1%
Revenue CAGR (3Y) -7.8% 0.9%
Gross profit growth (1Y) 52.4% 2.3%
Gross profit CAGR (3Y) -2.6% -0.4%
Operating income growth (1Y) 51.7% -5.5%
Operating income CAGR (3Y) 22.8% -3.7%
Net income growth (1Y) 52.7% -16.7%
Net income CAGR (3Y) 18.5% -33.8%
EPS growth (1Y) 55.7% -12.3%
EPS CAGR (3Y) 26.2% -31.2%
Operating cash flow growth (1Y) 83.0% 6.2%
Operating cash flow CAGR (3Y) -152.3% 86.9%
Free cash flow growth (1Y) 82.0% 9.5%
Free cash flow CAGR (3Y) -26.3% 64.8%

Profitability

14 metrics
MetricCDXSRVTY
Gross margin 87.0% 55.0%
EBITDA margin -27.0% 26.6%
Operating margin -35.6% 12.3%
Pretax margin -39.5% 9.0%
Net margin -39.6% 8.2%
FCF margin -15.7% 19.5%
Operating cash flow margin -13.4% 21.9%
Return on equity -80.6% 3.3%
Return on assets -24.6% 2.0%
Return on invested capital -35.1% 3.1%
Return on capital employed -27.3% 3.3%
Asset turnover 0.6x 0.2x
Cash conversion (OCF / net income) 0.3x 2.7x
Stock comp / revenue 9.9% 0.8%

Financial Health

11 metrics
MetricCDXSRVTY
Debt / assets 34.0% 26.6%
Debt / equity 1.2x 0.4x
Net debt / EBITDA 0.7x 2.8x
Debt / FCF -3.4x 5.6x
Liabilities / assets 72.5% 40.0%
Equity / assets 27.5% 60.0%
Interest coverage – 3.7x
Current ratio 3.1x 1.8x
Quick ratio 2.9x 1.4x
Cash ratio 2.3x 0.8x
Altman Z-score -6.13 3.38

Shareholder Returns

7 metrics
MetricCDXSRVTY
Dividend yield – 0.2%
Net buyback yield -0.3% 2.6%
Shareholder yield -0.3% 2.8%
Payout ratio (earnings) – 13.4%
Payout ratio (FCF) – 5.6%
Dividend growth (1Y) – -6.3%
Dividend CAGR (3Y) – -6.1%

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusCDXSRVTY
Forward P/E – 31.4xFY2026
EPS, next fiscal year $-0.37FY2026 $5.10FY2026
EPS growth, next FY – +0.8%FY2026
EPS growth, the year after – +11.0%
Revenue, next fiscal year $77.93MFY2026 $2.98BFY2026
Revenue growth, next FY +10.7%FY2026 +4.0%FY2026
Revenue growth, the year after +9.2% -2.0%

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersCDXSRVTY
Held by institutions 71.0% 100.0%
Institutions holding 148 545
Change in shares held, QoQ -2.4% -1.3%
Institutions buying 88 301
Institutions selling 36 161
Buyers to sellers 2.44 1.87

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

CDXSRVTY
CDXS 1.00 0.10
RVTY 0.10 1.00

Add a Peer

Largest companies in the same industry

Related Comparisons

Frequently Asked Questions

Which is bigger, CDXS and RVTY?

Revvity (RVTY) is the largest by market capitalisation: Codexis (CDXS) $115.64M, Revvity (RVTY) $18.07B.

Which company is growing faster?

Codexis (CDXS) grew revenue fastest over the trailing twelve months: Codexis (CDXS) +35.9%, Revvity (RVTY) +4.1%.

Which company is more profitable?

Revvity (RVTY) has the highest net margin (Codexis (CDXS) -39.6%, Revvity (RVTY) 8.2%). On return on invested capital, Revvity (RVTY) leads (Codexis (CDXS) -35.1%, Revvity (RVTY) 3.1%).

Which stock has performed better?

Over the past year Revvity (RVTY) returned the most: Codexis (CDXS) -51.9%, Revvity (RVTY) +62.1%. Over five years, Revvity (RVTY) compounded fastest (Codexis (CDXS) -47.8%/yr, Revvity (RVTY) -1.6%/yr). Returns are price only, before dividends.

Which pays a higher dividend?

Only one of these companies pays a dividend: Codexis (CDXS) 0.00%, Revvity (RVTY) 0.00%. Codexis (CDXS) pays no regular dividend.

Which stock is riskier?

By one-year price volatility, Revvity (RVTY) has been the steadiest (Codexis (CDXS) 86.8%, Revvity (RVTY) 39.9%). Volatility measures how widely the price swings, not the risk of the business.

Do CDXS and RVTY move together?

Their daily returns over the past year have a correlation of 0.10, a weak relationship. Holding both diversifies more than two closely linked stocks would.

Which is the better stock, CDXS and RVTY?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, Revvity (RVTY) leads on 7. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.